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Summary
Collagen arthritis (CA), an autoimmune model of rheumatoid arthritis (RA), has been studied
in various animals. However, it has not been studied in an animal with a genetic background
relevant to RA. We selected rats from a diabetic-resistant (DR) subline of the diabetic BB rat
because they have an autoimmune disease-prone background, but not the immunodeficiencies
of the diabetic BB rat, and the third hypervariable region (HVRIII) of the BB RTLDO gene
appeared to encode a nucleotide sequence of the human HLA D" gene, which has been reported
to be associated with susceptibility to RA. We synthesized oligonucleotide primers flanking
the RTLDO HVRIII, cloned polymerase chain reaction-amplified DNA into M13mp18, and
confirmed the presence of the susceptibility sequence (SS) (RRRAA) by the dideoxy sequencing
method in a colony ofDR BB/Wor-UTM rats. When immunized with human type II collagen
(CII) in incomplete Freunds adjuvant (IFA), arthritis developed rapidly by day 10 with 100%
incidence. Lightand electron microscopy revealed an unusually severe and aggressive, bidirectional
pattern of cartilage resorption by synovial and subchondral mononuclear and multinucleated
inflammatory cells. These findings coincided with a predominant humoral response to the cyanogen
bromide (CB) 11 fragment of the human CII molecule by the pathogenic IgG2a isotype. This
study provides further support to the role of CA as a relevant RA model, the specific roles of
the CB11 fragment as a major site of arthritogenic epitopes, and of antibody mechanisms in
the pathogenesis of CA. Furthermore, the identification of an RA SS in an immune response
gene of the DR BB rat presents a novel opportunity to determine with an animal model the
role of other antigens as well as this SS in RA.
R
ecent DNA sequence studies have established a molec-
ular basis for the association between rheumatoid
arthritis (RA)' susceptibility and HLA class II immune re-
sponse (Ir) genes (1). These studies indicate that the associa-
tion is linked specifically to the polymorphic, third hyper-
variable region (HVRIII) ofthe DR/3 gene. Those DRa alleles
associated with RA are marked by HVRRIIs, which code for
a five-member amino acid sequence between residues 69 and
' Abbreviations used in this paper. CA, collagen arthritis; CB, cyanogen
bromide; CII, type II collagen; DR BB, diabetic-resistant BioBreeding;
HVRIII, third hypervariable region; IDDM, insulin-dependent diabetes
mellitus; It, immune response; RA, rheumatoid arthritis; SS, susceptibility
sequence.
75 of theachain referred to as the RA susceptibility sequence
(SS). The SS is QRRAA for DR1-Dw1, QKRAA for DR4-
Dw4, QRRAA for DR4-Dw14, QRRAA for DR4-Dw15,
and RRRAA for DRw10 (1).
In reviewing a discussionby Todd et al. (1) on the subject
of Ir gene polymorphism in insulin-dependent diabetes mel-
litus (IDDM), we observed that the RA SS appeared to be
encoded by the HVRIII in the RT1.D# gene ofthe diabetic
BB rat. Numerous examples ofhomology between human,
rat, and mouse class II Ir genes have been recognized previ-
ously (2). The assignment ofrat RT1.D and RTLB, and mouse
MHC I-E and I-A genes as homologues of HLA-DR and
DQ Ir genes, are representative examples. These examples
are thought to be based upon framework homologies in which
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mouse Ir a genes. In contrast to these examples, our obser-
vation of the RRRAA sequence in the BB RTLDO gene
appeared to represent a novel example of HVR homology
in which a nucleotide sequence implicated as a susceptibility
sequence in RA is present within the HVRIII of a rat Ir
/3 gene.
Collagen arthritis (CA) is an autoimmune disease model
of RA (3). CA susceptibility is regarded as polygenic and
the full expression of the autoimmune disease process is
thought to represent theinteraction of multiple classII MHC
Ir andnonMHC genes (4-6). In the investigation conducted
herein, we selected the diabetic-resistant (DR) subline ofthe
diabetic BB rat to study CA. This subline was derived by
Dr. Arthur A. Like from a family of diabetic BB rats (7).
It has the autoimmune disease-prone genetic background of
the diabetic BB rat (8), but unlike the diabetic BB rat, this
sublinedoes notdevelop anyof theimmunologicalor patho-
logical problems associated with the diabetic condition (9).
Moreover, as we observed in the article by Todd et al. (1)
and confirmed in the investigation conducted herein, the
RT1.DO gene in this subline carries an RA SS, and thus,
this sublinealso has an Ir genebackground relevant specifically
to RA.
Materials and Methods
Source ofDR BB Rats.
￿
DR BB/Wor-UTM rats were obtained
from the University of Tennessee, Memphisbreeding colony. This
colony was established in 1984 by Dr. Solomon S. Solomon from
DR BB/Wor breeding stock supplied by Dr. Arthur A. Like,
Worcester, MA.In thecurrent studies, we used 45-55-d-old females.
Sequencing the HVRIII ofthe DR BB1WovUTM-RTI.DS Gene.
GenomicDNAwasextracted from freshly prepared liver tissue by
established methods(10). TheextractedDNAwasdiluted to 1 ng/pl
and digested with BamHI. A 1-pl aliquot of the digested DNA
was used as a template for amplification by the PCR(11). Oligo-
nucleotides complementary to regions flanking the BB RTI/DS
HVRIII were synthesized on a DNA synthesizer (model 380A;
AppliedBiosystems, Foster City, CA). These oligonucleotides were
designed so as to include notonly the complementary regionscor-
responding to the deducedamino acid positions 14-20 and 88-94
(12),but also unique restriction sites for HindlIIandXbal at their
respective 5' ends. The structures were 5' GAC GAA GCT TGA
GTG TCA TTT CTA CAA CGG G 3'and 5' CAG TTC TAG
ATC TCC GCG GCA CAA GGA ATC T 3'.
PCRs contained 10 mM Tris-HC1, pH 8.3, 50 mM KCI, 15
mM MgCl2, 0.01%a gelatin, 200 pM dATP, 200,uM dCTP, 200
pM dGTP, 200,AM dTTP, 1.0 pM of each primer, 1 ng template
DNA, 2.5 UTaqpolymerise (Perkin Elmer Cetus, Norwalk, CT).
ThePCRprofilewascomprisedof30cycles of30-s melting(95°C)
and annealing (50°C) steps, and a 1-min polymerization (72°C)
step. A263-bp amplifiedproductwas extractedwith phenol/chloro-
form andprecipitated with ethanol. The finalpellet wasredissolved
in 10 mM Tris, pH 8, 0.1 mM EDTA and digested with HindIII
and XbaI. Digested DNA was subjected to electrophoresis on a
3% Nusieveagarosegel, visualized by ethidium bromidestaining,
excised from thegel, and purified usingaGeneCleanKit (Bio 101).
The purified DNA was ligated into M13mp18 that had been
predigested with HindIII andXbal.Plaquescontaining inserts were
identified by blue/white selection. Positive plaques were selected
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forDNAextraction and sequencedusingSequenase enzyme (U.S.
Biochemical Corp., Cleveland, OH) andthe M13universalprimer
for dideoxy chain termination sequencing.
Immunizing DR BBIWor-UTM Rats with Human CIL Human
CIIwasextracted andpurified from articularcartilage by standard
limited pepsin digestion/salt precipitation methods(13) . Rats were
immunized with 0.2 ml of a water in oil emulsion containing
2 mg/mlnative human CIIin IFA(Difco Laboratories Inc., Detroit,
MI). This emulsion was prepared by homogenizing one part na-
tive human CII (4 mg/mlin 0.1 M acetic acid) into onepart IFA
at 4°C. The emulsion was injected intradermally at the base of
the tail. We also conducted comparative studies using native bo-
vine CII prepared from fetal cartilage by identical methods.
Determining theIncidence and Clinical Severity oftheArthritis.
￿
The
incidence of arthritis was determined by comparing the number
of rats with hindpawredness and swelling to the total number of
rats immunizedwith humanCII.Clinical severity wasdetermined
by comparing thevolume (ml) ofarthritichindpaws to thevolume
(ml) ofnonarthritic hindpaws. Hindpaw volumeswere determined
by taring abeaker ofmercury to zero on adigital balance, dipping
each hindpawinto themercuryto thelevelofthelateral malleolus,
recording thedisplacedweight in grams, anddividing this number
by the density of mercury.
Determining the Isotype andEpitope Specificity of theAntibody Re-
sponse. An ELISAwasused to determine theisotype andepitope
specificity of the antibody response to native human CII or rena-
tured cyanogen bromide (CB) peptides of human CII. The rena-
tured CB peptides were prepared by methodsdescribedpreviously
in detail (13). Allsteps in the ELISAwere done under 4°Ccondi-
tions. Serum samples were diluted in ELISA buffer (0.1 M Tris,
0.15 M sodium chloride, 0.1% Tween-20, pH 7.5) andincubated
on microtiter plates (polyvinyl SeroCluster Plates, Costar, Data Pack-
aging, Cambridge, MA) coated with either 10 gg native human
CII/ml0.145 M potassiumphosphate, pH 7.6, forisotype analysis
or 10 pg CB8, 9-7, 10, 11, and 12/m10.145 M potassium phos-
phate buffer, pH 7.6, for analyses of epitope specificity. Human
CII or CB peptide coating was done overnight. All subsequent
stepsused 1-h incubations. Thewellswere blockedwith 1% human
albumin(Buminate25%, Baxter Healthcare Corp., Glendale, CA)
in ELISA buffer before the addition of the sera. For isotype anal-
ysis, the plates were developed for rat IgM, IgG1, 2a, 2b, 2c, and
IgA by stepwise incubation with biotinylated mouse monoclonal
isotype reagents (Zymed Labs, South San Francisco, CA) and
peroxidase-conjugatedExtraAvidin (Sigma Chemical Co., St.Louis,
MO). For analysis of epitope specificity, the plates were developed
forrat IgG2a only, because of the predominance of the IgG2a re-
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Figure 1.
￿
The nucleotide sequence and deduced amino acid sequence
of the HVRIII of the RTLDO(u) allele in the DR BB/Wor-UTM rat.
Comparison with theS chainHVRIII sequencesfor those humanHLA
DRS alleles associated with RA reveals that theRA SS locatedbetween
residues 69 and75 is encoded by theRTLDS(u) allele in theDR BB/Wor-
UTM rat.
Allele
Human HIA DRS Alleles
Associated with RA (1)
GAG
E
CGG
R
AGG
R
CGG
R
GCC
A
GCG
A
GTG
V
GAC
D
ACC
T
TAC
Y
TGC
C
HIA DRI-DWI E Q R R A A V D T Y C
NIA DR4-Dw4 E Q K R A A V D T Y C
HIA DR4-D.14 E Q R R A A V D T Y C
HIA DR4-Dw15 E Q R R A A V D T Y C
HLA DRw10 E R R R A A V D T Y Csponse (see Results). OD values for isotype and epitope analyses
were determined at 490 nm with an automated ELISA reader (Mo-
lecular Devices, Menlo Park, CA).
Determining the Histopathologic Nature ofthe Arthritis.
￿
Standard
light and electron microscopic methods were used as described in
previous studies (14). In brief, the ankles were skinned; fixed in
3% glutaraldehyde, 0.1 M cacodylate, pH 7.4, for 3 d; decalcified
for 2 wk in 10% EDTA, 0.05 M Tris, pH 7.4, at4°C; cut sagitally;
and decalcified for another 2 wk. For light microscopy, the tissues
were embedded in paraffin, cut at 5 pm, and stained with 1% tolu-
idine blue. For electron microscopy, the tissues were embedded in
Araldite, cut at 1 um, and stained with 1% toluidine blue. These
thick sections were examined by light microscopy to select areas
for thin sections. Thin sections were stained in Reynolds lead-citrate
and examined in an electron microscope (1200; Jeol USA, Inc., Pea-
body, MA).
Results
Sequence ofthe HVRIII ofthe DR BB/Wor-UTM RTI.Df
Gene As shown in Fig. 1, the amino acid sequence of the
HVRIII between residues 69 and 75 of the RTLDS chain
was RRRAA as deduced from the nucleotide sequence of
PCR-amplified DNA cloned into M13mp18 and sequenced
by the dideoxy method. These results are in complete agree-
ment with those reported by Todd et al. (1) for BB rats ob-
tained from the Worcester colony as well as by Holowachuk
and Greer (15) for BB rats from the Toronto colony. As Fig.
1 also shows, this sequence is a member of the RA SSs as
revealed by comparisonwith the deduced amino acid sequences
of HVRRIIs of humanHLA DRa alleles associated with RA.
Incidence and Severity ofArthritis in Human CII Immunized
DR BB/Wor-UTMRats. The incidence of CA after immu-
nization with native human CII in the DR BB/Wor-UTM
rat was 100% in three separate studies (5 out of 5, 5 out
of 5, and 6 out of 6). The arthritis was evident clinically by
day 10 in 15 out of 16 rats; the other rat developed arthritis
on day 14. The arthritis in the hindpaws was bilateral in 15
out of 16 cases. The arthritic swelling in either hindpaw
amounted to an approximate doubling in hindpaw volume
as measured by mercury displacement. The means (range;
n) for left normal and arthritic hindpaws were 1.4 (0;3) and
2.7 (2.5-3.1; 6) indicating an increase in arthritic swelling
of 94%. Values for right normal and arthritic hindpaws were
1.5 (1.4-1.5; 3) and 2.8 (2.1-3.0; 6), indicating an increase
in arthritic swelling of 84%. Similar results were observed
in three comparative studies with native bovine CII in IFA
(3 out of 3, all on day 10; 5 out of 5, 4 on day 10, 1 on
day 13; 5 out of 5, all on day 10).
Isotype and Epitope Specificity of the Antibody Response to
Human CII. The isotype and epitope specificity of serum
antibody responses in human CII immunized, DR BB/Wor-
UTM rats were determined within 48 h of the onset of ar-
thritis which was day 10 for the data shown in Table 1. Iso-
type analysis revealed a predominance of IgG2a antibody to
human CII. The ELISA values in optical density units for
pooled serum were 0.218 for IgM, 0.023 for IgG1, >3.000
for IgG2a, 0.024 for IgG2b, 0.079 for IgG2c, and 0.023 for
IgA. As a result of the IgG2a predominance, the epitope
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specificity analysis shown in Table 1 was confined to an anal-
ysis of the IgG2a isotype only. As the data shows, CB11 was
the immunodominant epitope for the IgG2a antibody response
in arthritic BB rats immunized with human orbovine CII.
In contrast, this immunodominant CB11 response was rela-
tively suppressed in nonarthritic Brown-Norway rats im-
munized with native human CII for comparative purposes.
Histopathologic Nature ofthe Arthritis.
￿
Light microscopic
analysis of ankle joints from arthritic DR BB/Wor-UTM
rats revealed a bidirectional pattern of cartilage erosion. As
shown in Fig. 2, the arthritis began as a proliferative syno-
vitis with pannus formation at the joint margins. Cartilage
erosion occurred in the outer (unmineralized) layer of carti-
lage in association with this synovial tissue. Cartilage ero-
sion also occurred in the inner (mineralized) layer of carti-
lage. However, the erosions in thislayer were associated with
a marked inflammatory cell reaction originating from within
the subchondral compartment. As shown in Fig. 3 by elec-
tron microscopy, both mononuclear and multinucleated
inflammatory cell types were identified at sitesoferosion oc-
curring as a result of this reaction.
Discussion
In previous CA studies with DBA/1 mice, we demonstrated
that CA susceptibility correlates with an antibody response
that is directed predominantly against epitopes within the
CB11 fragment of the CII molecule (16), and that is restricted
in its expression to a pathogenic isotype such as IgG2a (6).
These studies and those more recently reported by Myers et
al. (17) clearly support this response as a major arthritogenic
response in the DBA/1 mouse model of CA.
One ofthe major questions raised by these studies has been
whether this arthritogenic response is peculiar to the I-Aq
Ir gene background ofDBA/1 mice. Their Ir gene background
is unusual in that only one of the two Ia isotypes is expressed;
i.e., I-A, the mouse homologue of human DQ (18). The I-E
isotype, the mouse homologue ofhumanDR, is not expressed.
Two other related questions raised in these studies havebeen
whether this response is peculiar to the use ofchick CII and/or
to the use of CFA. Precedents exist for an effect by the spe-
cies source of CII on CA susceptibility (19) and for an effect
by mycobacterial antigens in CFA on the quality ofimmune
responses in general (20).
Our aim in the present study was to select a strain of an-
imal with a genetic background relevant to RA, and to use
it as an RA research tool to study CA, specifically its ar-
thritogenic response to CII. Our selection of the DR BB
rat was based upon the following reasoning. (a) Unlike DBA/1
mice, DR BB rats express both Ia isotypes; i.e., RTLB and
RTLD, the rat homologues of human DQ and DR, respec-
tively (2, 21). (b) The DR BB RTLDO Ir gene carries a poly-
morphic sequence RRRAA implicated as an SS in RA. As
shown in Fig. 1 for the DR BB/Wor-UTMrat, this SS was
present in the correct location ofthe Ia a gene, i.e., between
codons 69 and 75 of the HVRIII, and in the correct la iso-
type, i.e., RTLD, the rat homologue of human HLA DR.
And (c), the DR BB rat which was derived from a familyTable 1 .
￿
The Epitope Specificity ofthe IgG2a Antibody Response to Renatured Human CH CB Peptides in DR BB/Wor--UTM Rats
With Collagen Arthritis
of diabetic BB rats (7), has the autoimmune disease-prone
genetic background (8), but not the immunodeficiencies of
the diabetic BB rat (9). This autoimmunedisease-prone genetic
background may consist of various non-Ir geneswhich may
be common to all HLA class II-linked autoimmune diseases
such as RA and IDDM (1), and which may be responsible
for promoting the full expression of the autoimmune mech-
anisms in these diseases as well as in animal models of these
diseases (6, 22).
When immunized with CII in the present study, we found
the DR BB rat to be markedly susceptible to CA. Arthritis
developed rapidly by day 10 with an incidence of 100%. This
marked susceptibility contrasts with that reported previously
in other rat strains studied by us and others in which arthritis
typically develops laterbetween days 12-24 and occurs with
a much lower incidence usually between 40 and 80% (3,
23-25). Our epitope and isotype analysis of the humoral re-
sponse at the onset of arthritis revealed an immunodominant
ELISAplates were coated with renatured CB peptides prepared from human CII as described in detail previously (13), and developed after incubation
with individual sera usingbiotinylated mouse monoclonal anti-rat IgG2a andExtraAvidin peroxidase. The results are shown in optical density units
for sera from arthritic DR BB rats immunized with human CII or bovine CII and diluted 1 :900 in ELISA buffer. For comparative purposes, ELISA
results also are shown for sera from nonarthritic Brown-Norway rats (Harlan, Indianapolis, IN) immunized with human CII and diluted 1 :300 in
ELISAbuffer. The bold numbers indicate the predominant IgG2a anti-human CII CB peptide value for each rat. Controls consisted of normal sera
assayed on CB peptide-coated wells or immune sera assayed on uncoated wells. The results in either case were <0.100 optical density units (data
not shown).
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IgG2a antibody response to the CB11 fragment of human
CII after immunization with either human or bovine CII
without mycobacteria. The arthritogenic antibody response
as defined in previous studies (6, 16) appears, therefore, to
be peculiar neither to DBA/1 mice, to the use of chick CII,
nor to the use of CFA. Moreover, in our comparative study
with the CA-resistant BN rat, this immunodominant IgG2a
response to CB11 was relatively suppressed. These results pro-
vide further support to the proposed role ofCB11 as a major
site of arthritogenic epitopes in CA. Since rat IgG2a, like
mouse IgG2a, is a pathogenicisotype (26), these results also
provide further support to the proposed role ofantibody mech-
anisms in the pathogenesis of CA (14).
In completing these immunological studies, we consid-
ered it important to verify the histopathological nature of
CA in the DR BB rat. In so doing, we observed that while
the nature ofits antibodyresponse did parallel that ofDBA/1
mice, the nature ofits histopathological response did not par-
Source of serum CB8
Anti-human CII CB
CB9-7 CB10
peptide ELISA
CB11
values
CB12 Total
Arthritic DR BB rats
Human CII Immunized (1 :900)
1 0.192 0.346 0.106 0.532 0.122 1 .298
2 0.017 0.397 0.203 0.564 0.204 1 .385
3 0.124 0.386 0.226 0.650 0.230 1 .616
4 0.294 0.496 0.246 0.741 0.292 2 .069
5 0.255 0.563 0.310 0.714 0.296 2 .138
Bovine CII Immunized (1 :900)
1 0.108 0.338 0.112 0.560 0.148 1.266
2 0.162 0.390 0.133 0.626 0.180 1.491
3 0.156 0.412 0.256 0.713 0.301 1.838
4 0.222 0.492 0.180 0.704 0.242 1.840
5 0.401 0.460 0.318 0.688 0.140 2.007
Nonarthritic Brown-Norway rats
Human CII Immunized (1 :300)
1 0.054 0.106 0.082 0.130 0.042 0.414
2 0.052 0.154 0.107 0.095 0.056 0.464
3 0.193 0.175 0.078 0.137 0.065 0.648
4 0.118 0.542 0.096 0.241 0.074 1 .071
5 0.196 0.374 0.186 0.370 0.147 1 .273Figure 2 .
￿
Development of a bidirectional pattern ofcartilage resorption in the tibia-tarsal joints ofDR BB rats with CA . Light micrographs were
taken of toluidine blue-stained sections from normal (A) and arthritic DR BB rats 10 (B), 13 (C), 21 (D and E), and30 (F) days after immunization
with human CH in IPA. As these micrographs show, cartilage resorption occurred at the joint margins in association with the synovial pannus (sp)
in b-d, and at central regions of the articular cartilage in association with a subchondral inflammatory reaction (sr) in c-f . The micrograph inE shows
that this subchondral inflammatory reaction in D (lower right area of tibia) at higher magnification .
allel that of DBA/1 mice (5, 27) . In fact, it did not parallel
that of other strains ofCAsusceptible rats studied previously
by us and others (3, 23-25) . The significant, bilateral swelling
observed in the ankles ofDRBB rats was associated initially
with the cartilage-erosive, synovial reaction typical of that
reported previously in other animals. However, in addition
to this reaction, we also observed the development ofpromi-
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nent inflammatory reactions originating from subchondral
regions and involving both mononuclear inflammatory cells
and multinucleated giant cells . These reactions appeared to
be responsible for much of the erosions occurring in the sub-
chondral bone and in the central regions of the articular car-
tilage .
Weknow from recent passive transfer studies that humoralFigure 3.
￿
Identification of mononuclear (mn) inflammatory cells and multinucleated giant cells (gc) associated with the subchondral inflammatory
reaction. Electron micrographs of tibia-tarsal sections from arthritic DR BB rats 21 d after immunization with human CII in IFA revealed the presence
ofmononuclear macrophage-like cells in A as well as giant cells adjacent to a subchondral blood vessel (bv) in B, and adjacent to sites of bone matrix
(bm) resorption in C and D. The giant cell in C contained several nuclei, only one of which is shown in this micrograph. The morphology of the
giant cells in C and D are consistent with that of cells actively degrading the bone martrix. In this regard, note in C the penetration of this giant
cell into the subchondral bone and in D the presence of large, endocytotic digestive vacuoles in this giant cell and the marked reduction in the collagen
fibril size and overall density of the bone matrix immediately adjacent to this giant cell.
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synovial reaction observed in CA (14). However, we do not
know presently whether these mechanisms alone are sufficient
to also provoke the subchondral inflammatory cell reactions
observed in DR BB rats with CA. These reactions could reflect
the production of antibodies with additional arthritogenic
specificities either to different epitopes within CB11 and/or
to epitopes within other CB peptides. In regard to this latter
possibility, we would like to note that while the major CB
peptide specificity of the antibody response in DBA/1 mice
and DR BB rats is similar, the fine specificity of this response
in these two animals is different. Thus, in DBA/1 mice the
predominant specificity is to CB11 followed by CB10 and
8, and then with a much lesser degree of specificity to the
other peptides (16). In DR BB rats, the predominant speci-
ficity also is to CB11, but is followed closely by CB9-7, and
then with a much lesser degree to the other peptides (Table
1). This difference in fine specificity, related undoubtedly to
the different Ir gene backgrounds ofthese animals (28), draws
attention to the potential role of CB9-7 as an additional site
of arthritogenic epitopes. It is relevant perhaps to note that
the antibody response to CB9-7 in the CA resistant BN
(RT1°) rat was weak compared to that in the CAsusceptible
DR BB (RTl°) rat as judged by comparing CB9-7 ELISA
values for sera diluted 1:300 and 1:900, respectively (Table
1). Regardless of whether the aggressive, bidirectional pat-
tern of cartilage resorption in the DR BB rat is related to
humoral mechanisms involving antibodies with additional
arthritogenic specificities or is related to other non-RT1 class
II-linked mechanisms unique to the genetic background of
the DR BB rat, the results presented herein clearly establish
it as a characteristic histopathologic feature ofCA in the DR
BB rat.
We would like to point out that this bidirectional pattern
is not unique to DR BB rats with CA. Bromley et al. (29)
have reported that the resorption of articular cartilage in RA
also exhibits a bidirectional pattern involving mononuclear
inflammatory cellsarising from the synovial tissues, and both
mononuclear and multinucleated giant cells arising from the
subchondral compartment. This bidirectional pattern could
be caused in part by cartilage immune complex mechanisms
similar to those described previously inpassive transfer studies
with CII antibodies from animals with CA (30). In support
of this suggestion, recent clinical studies of CII antibodies
from patients with RA show that (a) while the prevalence
of CII antibodies in RA sera is low, the prevalence of CII
antibodies in RA cartilage is high (13, 31); (b) epitope anal-
ysis reveals a predominance of CII antibodies directed against
the CB11 fragment (13); (c) IgG isotype analysis reveals a
predominance of the pathogenic IgG3 subclass (32); and (d)
in vitro experiments with a human cartilage immune com-
plex model implicate several potentially important pathogenic
mechanisms by which these antibodies could contribute to
the resorption of articular cartilage in RA (33).
The bidirectional resorption of articular cartilage in RA
represents a serious stage of this disease. The clinical studies
cited abovenot only serve to support the role ofautoimmune
mechanisms involving CII in this stage of the disease, but
also serve to raise several important questions relating ulti-
mately to the goal of developing more effective strategies for
treating this stage of the disease (34). These questions in-
clude, (a) What is the structureof the relevant arthritogenic
CII epitope(s) that initiates this autoimmune response; (b)
what is the structure of the T cell receptor(s) that responds
to it; and (c) what are the humoral and/or cellular effector
mechanisms that mediate the cartilage and bone destructive
consequences of this response? We suggest that the DR BB
rat model of CA presents a novel opportunity to begin to
answer these questions. As discussed herein, the DR BB/Wor-
UTM rat has an Ir gene background relevant specifically to
RA, and CA in this rat is associated with a similar bidirec-
tional pattern of cartilage resorption and humoral response
to human CII.
Finally, in addition to CII, avariety of other antigens have
been proposed as candidate arthritogens in RA (35). To date,
however, none ofthese other antigens has been examined for
arthritogenicity in an animal with a genetic background rele-
vant specifically to RA. Furthermore, while a molecular basis
for the association between RA susceptibility and HLA class
II Ir genes has been determined, a functional basis has not
been determined. We do not know how the presence of the
RA SS on a number of otherwise divergent HLA class II
haplotypes confers susceptibility to the development of RA
(1). Two well-defined hypotheses have been described: altered
antigen presentation and altered T cell reactivity (36). In the
former, theRA SS is thought to confer to the Iaot/Iaantigen-
presenting receptor increased binding and presentation to T
cells of some as yet unidentified arthritogenic peptide(s). In
the latter, the RA SS itself is viewed as an arthritogenic epi-
tope for a population of autoreactive T cells arising as a re-
sult of molecular mimicry between the RA SS on the HLA
DR(8 chain and the nuclear capsidantigen ofEBV (36). Con-
sidering the presence of the RA SS on the DR BB RTLDO
chain, we also suggest that the DR BB rat presents a novel
opportunity to test with an animal model the proposed role
of these other antigens as well as these proposed roles of the
SS in RA.
The authors gratefully acknowledge Kimberly Cox for oligonucleotide synthesis; Dorothy Durrant, Joyce
Champion, and Angela Williams for lightmicroscopy; Mary Melvin for electron microscopy; JosephJosephs
and Jayne Clark for photography; and Kathleen Pearson for manuscript preparation.
1337
￿
Watson et al.References
This work was supportedby National Institutes of Health grant AR39166 andby theVeterans Adminis-
tration Research funds.
Addresscorrespondence to Dr. William C. Watson, Veterans Administration Medical Center (151), 1030
Jefferson Avenue, Memphis, TN 38104.
Receivedfor publication 14 June 1990 and in revised form 31 July 1990.
1. Todd, J.A., H. Acha-Orbea, J.I. Bell, N. Chao, Z. Fronek,
C.O. Jacob, M. McDermott, A.A. Sinha, L. Timmerman, L.
Steinman, and H.O. McDevitt. 1988. A molecular basis for
MHC class II-associated autoimmunity. Science (Wash. DC).
240:1003.
2. Howard,J.C. 1983. Themajorhistocompatibility complexof
the rat: a partial review. Metabolism. 32:41.
3. Trentham, D.E., A.S. Townes, andA.H. Kang. 1977. Autoim-
munity to type II collagen: an experimental modelofarthritis.
J Exp. Med. 146:857.
4. Griffiths, M.M., andC.W.DeWitt. 1981. Immunogeneticcon-
trol ofexperimental collagen-induced arthritisin rats. II. ECIA
susceptibility andimmune response to type II collagen (CALF)
are linked to RT1. J Immunogenet. (Oxf). 8:463.
5. Wooley,P.H., H.S. Luthra, J.M. Stuart, and C.S. David. 1981.
TypeII collagen-induced arthritis in mice. I. Majorhistocom-
patibility complex (I region) linkage and antibody correlates.
J. Exp Med. 154:688.
6. Watson, WC., andA.S. Townes. 1985. Genetic susceptibility
to murine collagen II autoimmune arthritis.Proposed relation-
ship to theIgG2 autoantibody subclass response, complement
C5, major histocompatibility complex (MHC)andnon-MHC
loci.J Exp Med. 162:1878.
7. Butler, L., D.L. Guberski, and A.A.Like. 1983 . Geneticanal-
ysis of the BB/W diabetic rat. Can. J Genet. Cytol. 25:7.
8. Like,A.A., E.J. Weringer, A. Holdash, P McGill, D. Atkinson,
and A. Rossini. 1985. Adoptive transfer of autoimmune dia-
betes mellitus in BioBreeding/Worcester (BB/W) inbred and
hybrid rats. J Immunol. 134:1583.
9. Rossini, A.A., S. Slavin,B.A. Woda,M. Geisberg, A.A. Like,
andJ.P. Mordes. 1984. Totallymphoid irradiation prevents di-
abetes mellitus in the BioBreeding/Worcester (BB/W) rat. Di-
abetes. 33:543.
10. Greenberg, M.E.1988. CurrentProtocolsin MolecularBiology.
Greene Publishing Associates &Wiley-Interscience, NewYork.
2.2.1-2.2.3.
11. Bell,J. 1989. Thepolymerase chain reaction. Immunol. Today.
10:351.
12. Chao, NJ., L. Timmerman, H.O. McDevitt, andC.O.Jacob.
1989. Molecularcharacterization ofMHCclass II antigens (01
domain) in theBB diabetes-prone and -resistant rat. Immuno-
genetics. 29:231.
13. Terato, K., Y Shimozuru, K. Katayama, Y Takemitsu, I.
Yamashita, M. Miyatsu, K. Fujii, M. Sagara, S. Kobayashi,
M. Goto, K. Nishioka, N. Miyasaka, and Y Nagai. 1990.
Specificity of antibodies to type II collagen in rheumatoid ar-
thritis. Arthritis Rheum. 33:1493.
14. Watson, WC., P.S. Brown, J.A. Pitcock, and A.S. Townes.
1987. Passive transfer studies with type II collagen antibody
in Bi0.D2/old and new line and C57B1/6 normal and beige
(Chediak-Higashi) strains: evidence ofimportant roles for C5
1338 Diabetic-resistant BB Rat Response to Human Type II Collagen
and multiple inflammatory cell types in the development of
erosive arthritis. Arththritis. Rheum. 30:460.
15. Holowachuk, EW, and M.K. Greer. 1989. Unaltered class
II histocompatibility antigens andpathogenesis of IDDM in
BB rats. Diabetes. 38:267.
16. Terato, K., K.A. Hasty, M.A. Cremer, J.M. Stuart, A.S.
Townes, and A.H. Kang. 1985. Collagen-induced arthritis in
mice. Localization of an arthritogenic determinant to a frag-
ment of the type II collagen molecule.J. Exp Med. 162:637.
17. Myers, L.K., J.M. Stuart, J.M. Seyer, and A.H. Kang. 1989.
Identificationofan immunosuppressive epitopeof type II col-
lagenthat confers protection againstcollagen-induced arthritis.
J. Exp Med. 170:1999.
18. Tacchini-Cottier, F.M., and P.P. Jones. 1988. Defective EO ex-
pression in threemouse H-2 haplotypes resultsfrom aberrant
RNA splicing. J. Immunol. 141:3647.
19. Wooley, P.H., H.S. Luthra, M.M. Griffiths, J.M. Stuart, and
C.S. David. 1985. Type II collagen-induced arthritis in mice.
IV Variations in immunogenicregulation provideevidence for
multiple arthritogenic epitopes on the collagen molecule.J.
Immunol. 135:2443.
20. Leclerc, C., F. Audibert, and L. Chedid. 1978. Influence of
synthetic adjuvant (MDP) on qualitative and quantitative
changes of serum globulins. Immunology. 35:963.
21. Holowachuk, EX, M.K. Greer, and D.R. Martin. 1988.
Elevated mRNA levels of major histocompatibility complex
class II genes in lymphocytes of autoimmune BB rats. Diabetes.
37:1637.
22. Colle, E., R.D.Guttmann, TA. Seemayer, and F. Michel. 1983.
Spontaneous diabetes mellitus syndrome in the rat. IV Im-
munogenetic interactions ofMHCandnon-MHCcomponents
of the syndrome. Metabolism. 32:54.
23. Stuart, J.M., M.A. Cremer, A.H. Kang, and A.S. Townes.
1979. Collagen-induced arthritis in rats. Evaluation of early
immunologic events. Arthritis Rheum. 22:1344.
24. Terato, K., R. Hashida, K. Miyamoto, T Morimoto, Y. Kato,
S. Kobayashi, T Tajima, S. Otake, H. Hori, and Y Nagai.
1982. Histological, immunological, and biochemical studies
on type II collagen-induced arthritis in rats. Biomed. Res. 3:495.
25. DeSimone, D.P., D.B. Parsons, K.E. Johnson, andR.P.Jacobs.
1983. TypeII collagen-induced arthritis. A morphologic and
biochemical study of articular cartilage. Arthritis Rheum. 26:
1245.
26 . Farkas, A., G. Medgyesi, G. Fust, K. Miklos, andJ. Gergely.
1982. Immunogenicity of antigencomplexed with antibody.
I. Role of different isotypes. Immunology. 45:483.
27 . Holmdahl, R., L. Jansson, E. Larsson, K. Rubin, and L.
Klareskog. 1986.Homologous type II collagen induces chronic
and progressive arthritis in mice. Arthritis Rheum. 29:106.
28 . McDevitt, H.O., and B. Benacerraf. 1969. Geneticcontrol of
specific immune responses. Adv. Immunol. 11:31.29. Bromley, M., H. Bertfield, J.M. Evanson, and D.E. Woolley.
1985. Bidirectionalerosion ofcartilagein therheumatoid knee
joint. Ann. Rheum. Dis. 44:676.
30.; Watson, WC., A.S. Townes, and A.H. Kang. 1986. Im-
munopathogenicmechanisms in type 11 collagen autoimmune
arthritis. Pathol. Immunopathol. Res. 5:297.
31. Jasin, H.E. 1985. Autoantibody specificities of immune com-
plexes sequestered in articular cartilage of patients with rheu-
matoid arthritis and osteoarthritis. Arthritis Rheum.28:241.
32. Watson, WC., M.A. Cremer, P.H. Wooley, andA.S. Townes,
1986. Assessment of thepotential pathogenicityoftype II col-
lagenautoantibodies in patients with rheumatoid arthritis. Evi
denceof restricted IgG3 subclass expression and activation of
complement C5 to C5a. Arthritis. Rheum. 29:1316.
33. Watson, WC., and A.H. Kang. 1988. Cartilage bound au-
1339
￿
Watson et al.
toantibodies to type II collagen in rheumatoid arthritis: acti-
vators ofcomplement andinflammatorycells andproposed role
as "receptors" forrheumatoid factor.Proc 6thSEAPAL Congr
Rheum., 1st, Tokyo. 809:153.
34. Scott, D.L., B.L. Coulton, D.P.M. Symmons, andA.J. Popert.
1987. Long term outcome of treating rheumatoid arthritis:
results after 20 years. Lancet. 1108.
35. Bennett,J.C. 1989. Theetiology ofrheumaticdiseases. In Text-
book of Rheumatology. 3rd ed. W.N. Kelley, E.D. Harris,
S. Ruddy, and C.B. Sledge, editors. W.B. Saunders, Co.,
Philadelphia. 138-147.
36. Roudier, J., G. Rhodes,J. Petersen, J.H. Vaughan, and D.A.
Carson. 1988. The Epstein-Barr virus glycoprotein gp110, a
molecular link between HLADR4, HLADRl, and rheuma-
toid arthritis. Scand. J. Immunol. 27:367.